Prognostic impact of TP53 mutations in MDS with del(5q) and Q&A
. Jadersten M. 05/19/11; 7638
Disclosure(s): Celgene: participation in advisory board meeting 2009
CLICK HERE TO LOGIN
REGULAR CONTENT
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Learning Objectives
Discussion Forum (0)
Rate & Comment (0)
Critical evaluation of the role of treatment with lenalidomide in myelodysplastic syndromes with del(5q)
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}